Floatz logo

Tacrolimus

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

University of Michigan Rogel Cancer CenterSmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

38 Active assets in the Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB
Methotrexate
University of Michigan Rogel Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Tacrolimus is also rated in:

disease related to transplantationDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative · Phase 4
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →